US74584P3010 - Common Stock
PULMATRIX INC
NASDAQ:PULM (3/28/2024, 8:00:01 PM)
After market: 1.75 0 (0%)1.75
+0.13 (+8.02%)
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Bedford, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-03-21. Its inhaled therapeutic products based on its dry powder delivery technology, namely iSPERSE enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Its iSPERSE’s lead development program, PUR1900 is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. Its pipeline also includes PUR3100 for the treatment of acute migraine, and PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
PULMATRIX INC
36 Crosby Drive, Suite 100
Bedford MASSACHUSETTS 02421
P: 17813572333
CEO: Teofilo Raad
Employees: 28
Website: https://www.pulmatrix.com/
PULM stock results show that Pulmatrix beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulmatrix (NASDAQ:PULM) just reported results for the fourth quarter of 2023.Pu...
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
/PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Here you can normally see the latest stock twits on PULM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: